The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 20, 2026
Filed:
Jul. 06, 2021
Merck Sharp & Dohme Llc, Rahway, NJ (US);
Jacqueline D. Hicks, Watchung, NJ (US);
Rongze Kuang, Green Brook, NJ (US);
Christopher J. Sinz, Walnut Creek, CA (US);
Matthew J. Lombardo, Flemington, NJ (US);
Jovan Alexander Lopez, New Haven, CT (US);
Rohan Rajiv Merchant, Burlingame, CA (US);
Phillip Patrick Sharp, San Francisco, CA (US);
Zhicai Wu, Montvale, NJ (US);
Zhiqiang Zhao, Little Neck, NY (US);
Alan C. Cheng, San Francisco, CA (US);
Song Yang, San Francisco, CA (US);
Jianming Bao, Princeton, NJ (US);
Maoqun Tian, Forster, CA (US);
Galen Paul Shearn-Nance, Tiburon, CA (US);
Merck Sharp & Dohme LLC, Rahway, NJ (US);
Abstract
The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.